Expert Point of View: Andrew D. Zelenetz, MD, PhD


Get Permission

In the past, we considered multiple myeloma the poor sibling among lymphoid malignancies. We have seen an amazing amount of change in this field, and Dr. Anderson and colleagues have contributed to that progress. But despite the progress, most patients still relapse,” noted Andrew D. Zelenetz, MD, PhD, Vice Chair of Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, and Chair of the NCCN Congress on Hematologic Malignancies.

“Dr. Anderson gave a great overview of current and future strategies that may pan out to improve outcomes in multiple myeloma,” he noted at the NCCN Annual Congress. ■

Disclosure: Dr. Zelenetz reported no potential conflicts of interest.


Related Articles

New Strategies for Relapsed/Refractory Multiple Myeloma Explored

Although upfront therapy can achieve remission in multiple myeloma, most patients will ultimately relapse. Newer targeted therapies and genomic analysis are moving the management of relapsed/refractory multiple myeloma forward, according to Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple...

SIDEBAR: Take-Home Messages From the NCCN Hematologic Malignancies Conference

As the National Comprehensive Cancer Network (NCCN) 8th Annual Congress: Hematologic Malignancies was drawing to a close, The ASCO Post spoke with Andrew D. Zelenetz, MD, PhD, about the themes of the meeting and the take-home messages for attendees and for our readers. Dr. Zelenetz is Vice Chair...


Advertisement

Advertisement



Advertisement